These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 29856861

  • 1. Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.
    Kim H, Kwon HJ, Park SY, Park Y, Park E, Chung JH.
    PLoS One; 2018; 13(6):e0198634. PubMed ID: 29856861
    [Abstract] [Full Text] [Related]

  • 2. Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer.
    Yu H, Brustugun OT, Ekman S, Botling J, La Fleur L, Micke P, Solberg S, Berglund A, Rivard C, Hirsch FR.
    Clin Lung Cancer; 2021 Jul; 22(4):e555-e562. PubMed ID: 33214079
    [Abstract] [Full Text] [Related]

  • 3. Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.
    Pandey RK, Shukla S, Husain N, Islam MH, Hadi R, Kant Tripathi S, Singhal A.
    Asian Pac J Cancer Prev; 2022 Jan 01; 23(1):131-142. PubMed ID: 35092381
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
    Han K, Zhang Y.
    J Cancer Res Ther; 2019 Jan 01; 15(4):914-920. PubMed ID: 31436252
    [Abstract] [Full Text] [Related]

  • 11. The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC.
    Yang H, Chen H, Luo S, Li L, Zhou S, Shen R, Lin H, Xie X.
    Oncotarget; 2017 Apr 04; 8(14):23517-23528. PubMed ID: 28423587
    [Abstract] [Full Text] [Related]

  • 12. Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.
    Zheng Q, Huang Y, Zeng X, Chen X, Shao S, Jin Y, Xue Q, Wang Y, Guo Y, Gu B, Wu C, Li Y.
    J Cancer Res Clin Oncol; 2021 May 04; 147(5):1547-1556. PubMed ID: 33196892
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comprehensive analysis of PD-L1 in non-small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue.
    Wang CC, Huang KT, Chang HC, Tseng CC, Lai CH, Lan J, Liu TT, Huang CC, Lin MC.
    Thorac Cancer; 2022 Jan 04; 13(1):38-47. PubMed ID: 34841687
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.